Topics to be covered include:
- KINect Platform: Our Drug Discovery Engine
- ATI-450 (MK2 Inhibitor): An Oral Alternative to Injectable Anti-Cytokine Biologics and JAK Inhibitors for Immuno-Inflammatory Diseases
- ATI-1777: A “Soft” Topical JAK 1/3 Inhibitor
- ATI-2138: An ITK/TXK/JAK3 Inhibitor for Autoimmune Disease
- Gut Restricted Inhibitors of ITK and/or JAK Kinases as Drugs for Inflammatory Bowel Disease
The event will be webcast live over the Internet and can be accessed by logging on to the “Investors” page of the
About
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding the development of Aclaris’ drug candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and in commercialization of products, Aclaris’ reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended
Aclaris Contact
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
mtung@aclaristx.com
Source: Aclaris Therapeutics, Inc.